Deltex Medical Group (LSE:DEMG) ROCE % : -19.90% (As of Jun. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Deltex Medical Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Deltex Medical Group's annualized ROCE % for the quarter that ended in Jun. 2024 was -19.90%.

Deltex Medical Group ROCE % Historical Data

The historical data trend for Deltex Medical Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deltex Medical Group ROCE % Chart

Deltex Medical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-0.93

-15.44

-22.44

-28.05

-24.65

Deltex Medical Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-31.94	-20.12	-25.31	-31.55	-19.90

Deltex Medical Group ROCE % Calculation

Deltex Medical Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.052	/	( ( (6.013 - 2.475)	+	(5.932 - 0.934) )	/ 2 )
	=	-1.052	/	( (3.538	+	4.998)	/ 2 )
	=	-1.052	/	4.268
	=	-24.65 %

Deltex Medical Group's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-0.884	/	( ( (5.932 - 0.934)	+	(5.5 - 1.615) )	/ 2 )
	=	-0.884	/	( ( 4.998	+	3.885 )	/ 2 )
	=	-0.884	/	4.4415
	=	-19.90 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Deltex Medical Group (LSE:DEMG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Deltex Medical Group ROCE % Related Terms

Thank you for viewing the detailed overview of Deltex Medical Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Deltex Medical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Deltex Medical Group PLC (LSE:DEMG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DTXMF:USA

Address

Terminus Road, Chichester, West Sussex, GBR, PO19 8TX

Website

https://www.deltexmedical.com

Deltex Medical Group PLC is a British manufacturer of Fluid Management devices, which include the ODM and now ODM+ haemodynamic monitoring systems. The company has developed the gold standard for haemodynamic monitoring with oesophageal Doppler technology, which is marketed as TrueVue Doppler and often generically referred to by clinicians as ODM. The company's initial and principal technology is Doppler-based ultrasound oesophageal haemodynamic monitoring.

Deltex Medical Group Headlines

No Headlines